Dr Anne Phelan, Ph.D

Executive Vice President of Research

Anne joined Mission Therapeutics as Head of Discovery Research in March 2017.

Anne brings more than 25 years of experience in academic, Biotech and Pharma R&D.

Prior to joining Mission, Anne worked as VP Head of Drug Discovery at the London based Biotech BenevolentAI, where she headed up a team of scientists utilising the power of Artificial Intelligence to accelerate drug discovery across a wide range of therapy areas. Prior to BenevolentAI, Anne spent 16 years at Pfizer in the UK, where she held a number of senior roles within Research across a range of therapeutic and technology areas including Cardiovascular, Allergy and Respiratory, Genitourinary, Epigenetics, Primary Pharmacology and Pain Research Units. Roles included Chief Operating Officer (COO) for Pfizer Neusentis and Executive Director Head of Pharmacology for the Pain and Sensory Disorders Research Unit.

Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK.